New Cholesterol Pill Slashes Bad Cholesterol by 60%

Millions of people struggling with stubborn high cholesterol despite taking statins may soon have a powerful new weapon in a simple daily pill.

Researchers announced Wednesday that an experimental drug called enlicitide slashed artery-clogging LDL cholesterol by as much as 60% in high-risk patients. The results, published in the New England Journal of Medicine, represent a major breakthrough for people who can't get their "bad" cholesterol low enough with existing pill treatments alone.

The study followed nearly 3,000 patients for a year, all of whom were already taking statins but still faced dangerous cholesterol levels. Those who added the daily enlicitide pill to their treatment saw dramatic improvements. Their LDL cholesterol plummeted and stayed low throughout the 12-month trial, with no additional safety concerns compared to those taking a placebo.

"None come close to the degree of LDL cholesterol lowering that we see with enlicitide," said Dr. Ann Marie Navar, a cardiologist at UT Southwestern Medical Center who led the study.

Here's why this matters: Heart disease kills more Americans than any other condition, and high LDL cholesterol is a leading culprit. When cholesterol builds up in arteries, it creates plaque that can trigger heart attacks and strokes. Doctors recommend getting LDL levels below 70 for people with heart disease, and even lower for those at highest risk.

Statins like Lipitor and Crestor work well for many people, but plenty of patients still need extra help. Currently, the most powerful options are PCSK9 inhibitor injections that cost thousands of dollars and require regular shots. Very few patients who could benefit actually use them because of the hassle and expense.

The Bright Side

Enlicitide works the same way as those injections but in a simple pill form. This could remove major barriers that keep people from getting the treatment they need. No more expensive shots, complex insurance approvals, or anxiety about self-injecting.

The pill does need to be taken on an empty stomach, but that's a small trade-off for such powerful results. Merck, which funded the study, has applied for fast-track FDA approval.

There's one important caveat: researchers haven't yet proven the cholesterol reduction translates to fewer heart attacks and deaths. That kind of data takes years to collect. Merck currently has a study of more than 14,000 patients underway to answer that crucial question.

Dr. William Boden of Boston University called the research "compelling evidence" that the new pill matches the power of existing injections. The fact that benefits held steady over a full year is particularly encouraging.

For now, the results offer real hope that managing dangerous cholesterol levels could soon become much easier for millions of Americans fighting to protect their hearts.